Novavax is trading at $9.94, down 6.29%, after shares edged lower despite better-than-estimated Q3 results and higher full-year guidance. - Q3 revenue was $68.3 million and the loss was $0.19 per share, both better than cited analyst estimates. - Novavax raised full-year adjusted revenue guidance to $385–$415 million. - Coverage suggested investors wanted more; the broader market’s sharp decline may also weigh on trading. Positive sector context does not explain the drop.